What is the PERL study?
- Patients with Type 1 diabetes remain at risk for end-stage renal disease despite improvements in medicines that target blood pressure and gylcemic control
- The PERL study is a three-year, multi-center study evaluating the efficacy of the urate-lowering drug allopurinol, as compared to placebo, in reducing kidney function loss among subjects with T1D
How can I participate in the study?
- The PERL study is being conducted at the Joslin Diabetes Center in Boston, MA, the University of Minnesota in St. Paul/Minneapolis, MN, University of Colorado Denver in Aurora, CO, University of Michigan in Ann Arbor, MI, Northwestern University in Chicago, IL, Albert Einstein College of Medicine in Bronx, NY, Mount Sinai Hospital in Toronto, Ontario, and the Steno Diabetes Center in Copenhagen, Denmark
- Please click on the "Participating Sites" link above for site contact information